Define the Two Molecular Subtypes of Epithelioid Malignant Pleural Mesothelioma

Umair Ali Khan Saddozai 1, Fengling Wang 1, Saadullah Khattak 1*, Muhammad Usman Akbar 2*, Muhammad Badar 2, Nazeer Hussain Khan 1*, Lu Zhang 1, Wan Zhu 3, Longxiang Xie 1*, Yongqiang Li 1, Xinying Ji 1,* and Xiangqian Guo 1,*

1 Department of Preventive Medicine, Institute of Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China
2 Gomal Center of Biochemistry and Biotechnology, Gomal University, Dera Ismail Khan 29050, Pakistan
3 Department of Anesthesia, Stanford University, 300 Pasteur Drive, Stanford, CA 94305, USA

* Correspondence: 10190096@vip.henu.edu.cn (X.J.); xqguo@henu.edu.cn (X.G.)

Abstract: Malignant pleural mesothelioma (MPM) is a fatal disease of respiratory system. Despite the availability of invasive biomarkers with promising results, there are still significant diagnostic and therapeutic challenges in the treatment of MPM. One of three main mesothelioma cell types, epithelioid mesothelioma makes up approximately 70% of all mesothelioma cases. Different observational findings are under process, but the molecular heterogeneity and pathogenesis of epithelioid malignant pleural mesothelioma (eMPM) are still not well understood. Through molecular analysis, expression profiling data were used to determine the possibility and optimal number of eMPM molecular subtypes. Next, clinicopathological characteristics and different molecular pathways of each subtype were analyzed to prospect the clinical applications and advanced mechanisms of eMPM. In this study, we identified two distinct epithelioid malignant pleural mesothelioma subtypes with distinct gene expression patterns. Subtype I eMPMs were involved in steroid hormone biosynthesis, porphyrin and chlorophyll metabolism, and drug metabolism, while subtype II eMPMs were involved in rational metabolism, tyrosine metabolism, and chemical carcinogenesis pathways. Additionally, we identified potential subtype-specific therapeutic targets, including CCNE1, EPHA3, RNF43, ROS1, and RSPO2 for subtype I and CDKN2A and RET for subtype II. Considering the need for potent diagnostic and therapeutic biomarkers for eMPM, we are anticipating that our findings will help both in exploring underlying mechanisms in the development of eMPM and in designing targeted therapy for eMPM.

Keywords: mesothelioma; gene expression; molecular subtype; subtype-specific treatment

1. Introduction

Malignant pleural mesothelioma (MPM) represents a rare and violent neoplasm that primarily affects the pleural cavity [1,2]. It is a male-dominating disease, with almost 80% of cases occurring due to occupational or environmental exposure to asbestos [3–7]. Genetic susceptibility attached to asbestos exposure has recently been identified as a major factor in the development of malignant mesothelioma. The high number of micronuclei present in the peripheral blood lymphocytes of malignant mesothelioma patients could be a useful index to identify individuals’ susceptibility to the malignancy [8].

MPM has a poor prognosis rate, with a median survival between 6 and 12 months, and less than 5% of the 5-year survival rate [9–11]. Different therapies such as first-line therapy (1L), platinum chemotherapy, second-line immunotherapy (2L), or maintenance therapy are applied in clinical trials, but their outcomes are not promising [12–14]. Furthermore, only a small number of patients can be cured through surgery due to the late diagnosis of the disease [15,16]. Recently, significant studies on the carcinogenic behavior of asbestos and other fibers, and the genetic background of MPM have led to better understanding of
the disease [17–23]. According to the 2015 World Health Organization (WHO) histological lung and pleura tumor classification, malignant mesothelioma is classified into three major histological subtypes namely epithelial, biphasic and sarcomatoid [24,25], with the largest proportion of epithelial mesothelioma that has a better outcome as compared to the sarcomatoid and mixed type. Based on the response to treatment, epithelioid mesothelioma is heterogeneous. To promote the efficiency of recent therapies, finding ways to profile this group of patients with more accuracy, is vital for personalized treatment and new therapeutic options [26]. Different practices are under development to guide the treatment of cancers. For example, the recently developed gene expression profiling methods are used to facilitate the diagnosis and management of breast cancer, gastric cancer, leiomyosarcoma and pheochromocytoma [27–33]. The effective classification of cancers into distinct molecular subtypes helps cancer patients to have an improved diagnosis and to obtain more effective remedies [34]. So far, limited data about eMPM are enough for comparing it with different molecular subtypes. The current study used gene expression profiling data for molecular subtyping eMPM, two common eMPM molecular subtypes were measured, defined, and solidified with the 39 cases of the GSE29354 dataset and 57 cases of the TCGA dataset. Further identified various therapeutic genes and pathways in the analyzed molecular subtypes that may help develop the new target therapy specific to the eMPM molecular subtype.

2. Materials and Methods

2.1. Determination and Validation of Molecular Subtypes of eMPM

The expression profile of clinical eMPM cases was derived from TCGA and Gene Expression Omnibus (GEO) databases. The molecular subtypes of eMPM were defined based on two datasets, one from TCGA (57 cases) and the other of (GSE29354) from GEO (39 samples). After the individual expression datasets were filtered with standard deviation, gene-based centring was performed to transform the data. Using the Consensus clustering package Consensus Clustering Plus, both datasets were run separately through Consensus clustering with the following parameters: 80% resampling of the samples, 80% resampling of the genes, a maximum evaluated k of 12 after genetic clustering, distance (1-Pearson correlation), the agglomerative hierarchical clustering algorithm, and 1000 iterations to identify molecular subtypes [35]. Lastly, the accuracy of subtype assignment from Consensus Clustering Plus was determined by R package cluster (silhouette width) [36].

2.2. Reproducibility Measurement of eMPM Molecular Subtypes

The reproducibility of eMPM molecular subtypes between TCGA and GSE29354 cohorts was determined through Subclass Mapping (SubMap) implemented in GenePat-tern, with parameters of Num.marker.Genes = 300, num.perm = 1000 and num.per.fisher = 1000 [37].

2.3. Gene Ontology and Gene Set Enrichment (Gsea) Analysis

SAM [38] and SAMseq [39], with less than 0.05 false discovery rate, were applied to identify genes specific to each subtype. DAVID Bioinformatics Resources Online version 6.7 (https://david.ncifcrf.gov/ (accessed on 1 July 2022)) (accessed on 1 July 2022)) was also used for GO and KEGG pathway analysis. GSEA [40] analysis was used to examine the expression levels of genes and pathways particular to every subtype. Moreover, the TARGET V2 database (http://www.broadinstitute.org/cancer/cga/target (accessed on 1 July 2022)) explored the potential therapeutic genes of each eMPM subtype.

2.4. Statistical Analysis

To evaluate whether the association between clinical factors and subtypes of eMPM is statistically significant, Fisher exact test and chi-square test were applied, and a p-value less than 0.05 was considered significant. In addition, the Kaplan–Meier plot and log-rank test were performed by Graphpad Prism 7 software. The seven targeted genes were
also analyzed by GEPIA to assess the overall survival (OS) and prognostic value of these genes [41].

3. Results
3.1. Consensus Clustering Identified Two Different Empm Molecular Subtypes

Consensus clustering was used for the identification of eMPM subtypes based on their gene expression profiles. Initially, the curve of empirical cumulative distribution (CDF) (Figure 1A–C) revealed that the TCGA cohort with 57 eMPM samples has two optimal molecular subtypes. The results of Consensus clustering were confirmed by silhouette width analysis. It was found that 55 out of 57 samples had a positive silhouette value, thus used for later analysis. Among 55 samples, 44 were of subtype I, while 11 samples belonged to subtype II (Figure 1D).

**Figure 1.** The TCGA cohort of eMPM, represented two molecular subtypes. (A) Using an empirical cumulative distribution plot, the optimal number of eMPM molecular subtypes was found. (B) Comparative increase in the area under the CDF curve along with increasing expected number of molecular subtypes. (C) Matrix of Consensus clustering for the two unique eMPM subtypes. (D) Silhouette plot of eMPM based on Consensus clustering assignment.
3.2. Validation of eMPM Molecular Subtypes by Independent Dataset

The two subtypes of eMPM from the TCGA cohort were further verified by analyzing a GEO dataset (GSE29354) with 39 eMPM cases. In the GSE29354 dataset, Consensus clustering did also identify two molecular subtypes (Figure 2). Like the TCGA dataset, positive silhouette cases obtained in the GSE29354 dataset were used for further analysis.

Figure 2. The TCGA cohort of eMPM represented two molecular subtypes. (A) An empirical cumulative distribution plot used to determine the optimal number of molecular subtypes for eMPM (B). Compared to the prediction of the number of molecular subtypes found using the CDF curve, the area under the CDF curve has increased (C). For the two distinct eMPM subtypes, a Consensus clustering matrix has been developed (D). Based on the Consensus grouping assignment, a silhouette plot of the eMPM has been created.

3.3. SubMap Analysis of Molecular Subtypes in Independent Empm Cohorts

SubMap analysis was performed to evaluate the correlation between two different molecular eMPM subtypes in independent datasets. It was revealed that the A1–A2 subtypes of TCGA were significantly correlated with the B1–B2 subtypes of GSE29354 (Figure 3). This indicates that the molecular subtypes are common and reproducible across different eMPM cohorts.
3.4. Clinical Characteristics of eMPM Molecular Subtypes

The eMPM molecular subtypes in the TCGA cohort were clinically characterized by studying the relationship between these subtypes and their clinical factors. It was found that right sides had a remarkably higher laterality rate for both eMPM subtypes, which is 72.2% in subtype I and 54.5% in subtype II (Supplementary Table S1, $p = 0.3492$). In this dataset of eMPM the number of patients from subtype I was found to be higher (44/57) as compared to the subtype II (11/57) ($p = 1$) and a maximum number of patients belongs to stage III cancer in which subtype I found at high risk that is (54.5%) ($p = 0.58$).

Whereas 463 days were recorded as the median overall survival time (OS) of eMPM subtype II patients, the time slightly shorter than the survival time of subtype I patients, which was recorded to be of 791 days ($p = 0.0049^*$). Kaplan–Meier plots (KMP) curve analysis showed significant difference between the overall survival rates of the two eMPM subtypes. The red line of KMP represents the OS of subtype II patients while the black line represents the OS of subtype I patients (Figure 4). (Supplementary Table S1). We further found that all the targeted genes with low and higher expression levels presented different overall survival (OS) in both subtypes of epitheloid malignant pleural mesothelioma. Higher overexpression of all 5-subtype I including CCNE1, EPHA3, RNF43, ROS1 and RSPO2 genes show low overall time survival and lower expression levels show the longer overall survival time. Whereas the higher rate of overexpression in two target genes (CDKN2A and RET) represent high OS and lower expression show the small OS time in mesothelioma. The significance rate of CCNE1 ($p = 2.1 \times 10^{-5}$), EPHA3 ($p = 0.25$), RNF43 ($p = 0.77$), ROS1 ($p = 0.0035^*$) and RSPO2 ($p = 0.03^*$) for subtype I and CDKN2A ($p = 5.9 \times 10^{-7}$) and RET ($p = 0.46$) for subtype II (Figure 5).

3.5. Functional Analysis of eMPM Subtype-Specific Genes

Differential gene expression of two eMPM molecular subtypes in the TCGA dataset was analyzed by SAMseq analysis. It was revealed that 1520 genes had differential expression between the two subtypes, out of which 1161 genes had overexpression in subtype I and down-expression in subtype II eMPM. In contrast, the 359 genes were upregulated in subtype II and down-regulated in subtype I (Supplementary Table S2).
The top 200 upregulated genes from each eMPM subtype were further analyzed by KEGG and GO to find additional biological information about the subtypes. Subtype I was revealed by GO analysis to be enriched with 50 different biological processes, including negative regulation of glucuronosyltransferase activity (2.73%) (Supplementary Table S3). Analysis of upregulated genes in subtype I by KEGG revealed 15 different pathways belonging to steroid hormone biosynthesis, porphyrin and chlorophyll metabolism, drug metabolism, and other enzyme pathways, etc. (Figure 6A). In the case of subtype II eMPM,
it was found to be significantly enriched with 32 biological processes and 7 KEGG pathways, including rational metabolism, tyrosine metabolism, chemical carcinogenesis pathways, etc. (Figure 6B). Moreover, demonstration of TCGA cohort gene sets by GSEA analysis showed that 2922 gene sets with GSEA in TCGA dataset, 1979 gene sets were shown to be enriched in two subtypes, with 1568 of them overexpressed in subtype I and the remaining 411 overexpressed in subtype II (Table 1). Besides this, subtype I was rich in significant biological pathways, including ECM receptor interaction and WP gastric cancer network. Subtype II analysis found pathways of fatty acid metabolism and pathway of cytoplasmic ribosomal proteins (Figure 7B, C).

![Figure 6](image)

**Figure 6.** Pathways enriched in epithelioid malignant plural mesothelioma subtypes. (A) Subtype I KEGG pathways of eMPM. (B) KEGG pathways in subtype II eMPM.

**Table 1.** Number of overexpressed and down-expressed genes set in eMPM.

|                        | Subtype I | Subtype II |
|------------------------|-----------|------------|
| 1979 gene sets         | 1568      | 411        |
| FDR < 25%              | 175       | 68         |
| Nominal p-value < 5%   | 245       | 81         |
| Nominal p-value < 1%   | 141       | 47         |

### 3.6. Clinical Implication of eMPM Subtyping

The molecular subtyping of eMPM was performed to search and identify therapeutic ways and to apply these specified routes for further clinical studies and discourses. For the determination of therapeutic molecules, the genes upregulated in both eMPM subtypes were compared with the TARGET database containing target genes and functional inhibitors [11]. However, further studies may be required for the targeted genes to be translated into potential clinical stages [42–44]. The current study has found seven target genes specific to each subtype, based on which eMPM patients from certain subtypes would gain relative benefits. A total of five target genes, namely **CCNE1, EPHA3, RNF43, ROS1, and RSPO2**, can benefit subtype I eMPM patients, while subtype II patients can benefit from two target genes, i.e., **CDKN2A and RET** (Table 2).
Figure 7. Different gene expression signatures in different eMPM molecular subtypes are shown by GSEA. (A) Different gene expression patterns in subtype I and subtype II are represented. Genes that are overexpressed are red, while genes that are under-expressed are blue. (B) In subtype I, GSEA demonstrates the activity of the ECM receptor interaction and WP gastric cancer network. (C) In subtype II, GSEA revealed the activation of the fatty acid metabolism pathway and cytoplasmic ribosomal proteins pathways.

Table 2. Target genes enriched in each molecular subtype of eMPM.

| Gene Overexpressed | Examples of Potential Therapeutic Agents |
|--------------------|------------------------------------------|
|                    | **CCNE1**                                | CDK2 inhibitor |
| **Subtype I**      | EPHA3 | Dasatinib, Ephrin inhibitors |
|                    | RNF43 | Porcupine inhibitors |
|                    | ROS1  | Crizotinib |
|                    | RSPO2 | WNT inhibitors |
| **Subtype II**     | CDKN2A | CDK4/6 inhibitors |
|                    | RET   | Sorafenib, vandetinib, RET inhibitors |

4. Discussion

The most common and primary type of pleural malignancy is malignant pleural mesothelioma (MPM). It exhibits a poor prognosis because of its highly aggressive clinical nature [45]. Early diagnosis of MPM may increase the survival rate of MPM patients. Presently, it is hypothesized about the treatment of MPM in different studies that even the administration of identical treatment to the patients at the same stage of the disease may result in different responses owing to molecular heterogeneity [46,47].

Molecular subtyping of tumors based on gene expression profiling has aided in the development of subtype-specific diagnosis, prognosis, and therapies [35]. A suitable exam-
ple of subtype targeted therapies is the herceptin treatment trial in breast cancer. Patients with HER2-negative breast cancer did not benefit from herceptin treatment, whereas those with HER2-positive breast cancer responded substantially and benefited from it [48].

Though the World Health Organization (WHO) classifies MPM into epithelioid, sarcomatoid, and mixed (biphasic) subtypes, the actual spectrum of tumors is completely overgeneralized by this division. Although the epithelioid subtype possesses a limited number of prognosis and survival data, this study took a better step to use the limited data and identify the molecular subtypes based on gene expression profiles, and propose proper targeted therapies for eMPM.

The gene expression profiling method can make it possible to characterize the biological diversity of eMPM, and it also provides the opportunity for the development of therapeutic strategies specific to the subtype.

This study identified two molecular eMPM subtypes [49](also confirmed by de Reyniès et al.). The gene expression profiling method revealed 39 cases in the GSE29354 dataset and then validated in the TCGA cohort with 57 eMPM cases. In both of these, certain specific genes and pathways were revealed by gene set enrichment and gene ontology analyses to be overexpressed (Supplementary Table S4). Genes overexpressed in subtype I eMPM included DKK1 and CPS1 (Figure 7), enriched the pathways including steroid hormone biosynthesis, porphyrin, chlorophyll metabolism, drug metabolism, etc. (Figure 6). A recent study revealed that the pattern of miRNA expression in MPM is highly uncontrolled, and a 2-miRNA signature might be a potentially helpful tool for MPM prognosis [50]. Data indicated T-type Ca^{2+} channel expression in malignant mesothelioma (Mme) tissue and their participation in epigallocatechin-3-gallate (EGCG)-specific cytotoxicity to MMe cells, implying that these channels might be used as a novel MMe pharmaceutical target [51]. An unanticipated link between ERb-mediated tumor suppression and energy metabolism is another option to improve the treatment of malignant mesothelioma [52]. Owing to its role in regulating tumor progression by inhibiting the classical Wnt pathway [53,54], most studies define Dkk1 as a biological marker with the potential to evaluate tumor diagnosis and prognosis [55–57]. It has been recognized by some studies that Dkk1 can be overexpressed in several different cancer cell lines, including liver, lung, breast, glioma, and cervical cancer, and it inhibits cell proliferation and differentiation by inducing apoptosis [58,59]. CPS1 (carbamoyl phosphate synthetase 1) is a multidomain enzymatic protein found in mitochondria, liver, and intestine that catalyzes the first committed step of the urea cycle for ammonia detoxification and disposal [60]. A potent study showed the overexpression of CPS1 has been linked to both unfavorable therapeutic responses in colorectal cancer patients receiving neoadjuvant concurrent chemoradiotherapy, according to new research (CCRT) [61]. Pham-Danis et al. recently discovered that inhibiting CPS1 with EGFR inhibitors can lower the proliferation of EGFR-mutant non-small cell lung cancer (NSCLC) cells and stop them from progressing through the cell cycle [62]. In addition, The Cancer Genome Atlas (TCGA) has revealed the high expression of the CPS1 gene in a variety of cancer types, including bladder, colon, esophageal, endometrial, lung, and prostate cancers [63].

Rational metabolism, metabolism of tyrosine, chemical carcinogenesis, etc., are the pathways that are enriched in subtype II, while LAMP3 is the gene that is overexpressed in this subtype (Figure 6). Primarily, LAMP3 was reported in lung tissues but is found to have overexpression in multiple primary cancers, including breast, lung, and liver cancers [64]. Moreover, LAMP3 is considered a suitable biomarker for breast cancer as it is associated with the progress regulating hypoxia [65], and its expression in epithelial cells is reported to evaluate the prognosis of esophageal squamous cell carcinoma [66]. It was also found that LAMP3 is one of the genes that are highly upregulated in osteosarcoma lung metastasis tissue than in conventional osteosarcoma tissue [67]. Studying the expression of each subtype’s specific genes and pathways will be a better way to understand eMPM at the subtype level and help develop treatment strategies against specific subtypes.
A recent study suggests that disease occurrence takes place primarily from the loss of tumor suppressor gene function, and there are no “druggable” driver oncogenes associated with MPM [68]. However, in our molecular subtyping, different genes and pathways expressed in each subtype were further compared with the TARGET database. For the two eMPM subtypes, seven known target genes were identified (Table 2). Genes, namely CCNE1, EPHA3, RNF43, ROS1, and RSPO2, were found to be overexpressed in subtype I eMPM, whereas CDKN2A and RET were the genes overexpressed in subtype II. Therefore, the subtype-specific molecular characterization might translate into “druuggability” in the future.

CCNE1, along with its catalytic subunit CDK2, has a key role in regulating the cell cycle, for it assures precise control of DNA replication, chromosome segregation, and the G1 to S-phase transition [69,70]. Expression of CCNE1 has been reported in various cancers such as bladder cancer [71], colorectal cancer [72], gastric [73], high-grade serous ovarian carcinomas (HGSCs) [74] and ovarian cancer [75]. Due to its relative specificity for cyclin E and the critical function CDK2 plays in the activated CDK2/cyclin E1 complex, CDK2 is an appealing target in the treatment of CCNE1 amplified malignancies. In vitro, the targeted inhibition of CDKs using pan-CDK inhibitors and, more specifically, CDK2 inhibitors have shown promise in CCNE1-amplified malignancies [76,77]. Pan-CDK inhibitor, e.g., dinaciclib (SCH-727965), has been clinically tested to inhibit CDKs 2/5/1/9 involved in hematological and solid malignancies (NCT00798213 and NCT00937937) [78,79]. A similar outcome was also reported with the correspondence to the survival rates and detection of cancer. There are several oncogenic proteins such as EPHA3 and RSPO1, RSPO2, and RSPO3, which are overexpressed in lung adenocarcinomas and lymphoblastic leukemia and define the patient’s survival rates [80–82]. Similarly, mutations of RNF43 and RNF43/ZNRF3 or RSPOs also play a pivotal role in the activation of oncogenic pathways in various cancers and determine the cancer onset [83–87]. Hence, multiple approaches are being developed by using these marker proteins as therapeutic targets. For example, dasatinib is used in the activation of EphA3 via mediating role of the ABL1 protein kinase domain in lymphoblastic leukemia, and PORCN is considered suitable for the palmitoleation of mammalian Wnts to treat ovarian cancer. These targets are being extensively explored for better understanding and are evaluated in clinical trials in oncological settings [88–95]. Another latest study of malignant pleural mesothelioma (MPM) also presented the CD74-ROS1 fusion for the first time with a complete and long-term response to crizotinib [96]. Thus, the possible use of these inhibitors may play a significant role in subtype I of eMPM.

P16INK4a encoded by cyclin-dependent kinase (CDK) inhibitor 2A (CDKN2A) regulates the cell cycle by inhibiting CDK4/6. Mutation or loss of CDKN2A has been detected in various malignancies and results in increased CDK activity [97]. CDKN2A deletion frequency in MPM varies from 61% to 88% in primary tumors, with some studies suggesting deletion in only one-fifth of the cases of MPM [98–104]. The arrival of FDA-approved anti-CDK4/6 inhibitors (palbociclib and ribociclib) for breast cancer metastasis has made it targeting cell cycle dysregulation more accessible [105]. Palbociclib has also exhibited encouraging results against patients with liposarcoma [106] and CDKN2A-mutated non-small cell lung cancer [107]. Moreover, tyrosine kinase receptor (TKR)-targeted antibodies and tyrosine kinase inhibitor (TKI) related micro molecules have aroused another ray of hope in treating different cancers by blocking the TKR and subsequent molecular signaling [108]. The rearranged during transfection (RET) proto-oncogene can act as a potential therapeutic TKR target for TKIs such as carbozantinib, vandetanib, sunitinib, and sorafenib. They are primarily targeted in thyroid carcinomas and NSCLC’s RET. Patients suffering from malignant mesothelioma (MM) can also benefit from similar therapeutic targeting [109].

To the best of our knowledge, the current study revealed the overexpression of CDKN2A first time in eMPM. Therefore, investigating the role of these inhibitors in eMPM and patient selection based on such molecular characteristics becomes vital for the success of future clinical studies.
In conclusion, we defined distinct intrinsic molecular subtypes of eMPM with different gene signatures in two independent cohorts. Our findings provide insight into the understanding of the malignancy development and progression of eMPM and provide valuable information to develop individualized subtype-specific therapies for eMPM.

**Supplementary Materials:** The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cells11182924/s1, Table S1: Clinicopathologic Characteristics of eMPM (N = 57). Table S2: Results of SAM analysis between different subtypes of eMPM in TCGA. Table S3: Biological process enriched in each subtype of Mesothelioma. Table S4: Biological process (KEGG) enriched in each subtype of Mesothelioma.

**Author Contributions:** Conceptualization and Methodology, X.G.; Software, X.G. and U.A.K.S.; Validation, X.G. and U.A.K.S.; Formal analysis, X.G., U.A.K.S., F.W. and L.Z.; Investigation, U.A.K.S. and X.G.; Resources, X.G., X.J. and Y.L.; Data curation, U.A.K.S. and X.G.; Writing—original draft, U.A.K.S., M.U.A., W.Z. and X.G.; Writing—review and editing, U.A.K.S., M.U.A., W.Z., X.G., X.J., M.B., S.K., N.H.K. and L.X.; Visualization, U.A.K.S.; Supervision, X.G., X.J. and Y.L.; Project administration, X.G., X.J. and Y.L.; Funding acquisition, X.G. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported by Science and Technology, Department of Henan Province (No. 192102310350) and Science and Technology Department of Henan Province (192102310379). The funding bodies were not involved in the study design, data collection, analysis and interpretation of data, or writing of this manuscript.

**Data Availability Statement:** The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

**Acknowledgments:** Henan Province Science and Technology Department has funded this work. The study was designed, and data were collected, analyzed, interpreted, and reported in this manuscript without the involvement of the funding bodies (192102310379) and (192102310350), respectively. Either of the funding bodies did not influence this manuscript.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Ismail-Khan, R.; Robinson, L.A.; Williams, C.C., Jr.; Garrett, C.; Bepler, G.; Simon, G.R. Malignant pleural mesothelioma: A comprehensive review. *Cancer Control.* 2006, 13, 255–263. [CrossRef]
2. Segura-González, M.; Urias-Rocha, J.; Castelán-Pedraza, J. Malignant Mesothelioma of the Tunica Vaginalis: A Rare Neoplasm—Case Report and Literature Review. *Clin. Genitourin. Cancer* 2015, 13, e401–e405. [CrossRef]
3. Jasani, B.; Gibbs, A. Mesothelioma Not Associated With Asbestos Exposure. *Arch. Pathol. Lab. Med.* 2012, 136, 262–267. [CrossRef]
4. Roe, O.D.; Stella, G. Malignant pleural mesothelioma: History, controversy and future of a manmade epidemic. *Eur. Respir. Rev.* 2015, 24, 115–131. [CrossRef]
5. Gazdar, A.F.; Carbone, M. Molecular Pathogenesis of Malignant Mesothelioma and its Relationship to Simian Virus 40. *Clin. Lung Cancer* 2003, 5, 177–181. [CrossRef]
6. Carbone, M. Simian virus 40 and human tumors: It is time to study mechanisms. *J. Cell. Biochem.* 2000, 76, 189–193. [CrossRef]
7. Carbone, M.; Rizzo, P.; Pass, H. Simian virus 40: The link with human malignant mesothelioma is well established. *Anticancer Res.* 2000, 20, 875–877. [PubMed]
8. Bolognesi, C.; Filiberti, R.; Neri, M.; Perrone, E.; Landini, E.; Canessa, P.A.; Simonassi, C.; Cerrano, P.G.; Mutti, L.; Puntoni, R. High frequency of micronuclei in peripheral blood lymphocytes as index of susceptibility to pleural malignant mesothelioma. *Cancer Res.* 2002, 62, 5418–5419. [CrossRef]
9. Jaklitsch, M.M.T.; Grondin, M.S.C.; Sugarbaker, M.D.J. Treatment of Malignant Mesothelioma. *World J. Surg.* 2001, 25, 210–217. [CrossRef]
10. Robinson, B.W.; Lake, R.A. Advances in Malignant Mesothelioma. *New Engl. J. Med.* 2005, 353, 1591–1603. [CrossRef]
11. Van Allen, E.M.; Wagle, N.; Stojanov, P.; Perrin, D.L.; Cibulskis, K.; Marlow, S.; Jane-Valbuena, J.; Friedrich, D.C.; Kryukov, G.; Carter, S.L.; et al. Whole-exome sequencing and clinical interpretation of formalin fixed, paraffin-embedded tumor samples to guide precision cancer medicine. *Nat Med.* 2014, 20, 682–688. [CrossRef] [PubMed]
12. Meirson, T.; Pentimalli, F.; Cerza, F.; Baglio, G.; Gray, S.G.; Correale, P.; Krstic-Demonacos, M.; Markel, G.; Giordano, A.; Bomze, D.; et al. Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma. *JAMA Netw. Open.* 2022, 5, e221490. [CrossRef]
13. Messori, A.; Trippoli, S. Current treatments for inoperable mesothelioma: Indirect comparisons based on individual patient data reconstructed retrospectively from 4 trials. *J. Chemother.* 2022, 12, 1–5. [CrossRef] [PubMed]

14. Kerrigan, K.; Jo, Y.; Chipman, J.; Haaland, B.; Puri, S.; Akerley, W.; Patel, S. A Real-World Analysis of the Use of Systemic Therapy in Malignant Pleural Mesothelioma and the Differential Impacts on Overall Survival by Practice Pattern. *JTO Clin. Res. Rep.* 2022, 3, 100280. [CrossRef] [PubMed]

15. Baumann, F.; Flores, E.; Napolitano, A.; Kanodia, S.; Taioli, E.; Pass, H.; Yang, H.; Carbone, M. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. *Carcinogenesis* 2015, 36, 76–81. [CrossRef]

16. Ricciardi, S.; Cardillo, G.; Zirafa, C.C.; Carleo, F.; Facciolo, F.; Fontanini, G.; Mutti, L.; Melfi, F. Surgery for malignant pleural mesothelioma: An international guidelines review. *J. Thorac. Dis.* 2018, 10, S285–S292. [CrossRef]

17. Bononi, A.; Napolitano, A.; Pass, H.I.; Yang, H.; Carbone, M. Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies. *Expert Rev. Respir. Med.* 2015, 9, 633–654. [CrossRef]

18. Altomare, D.A.; Menges, C.W.; Pei, J.; Zhang, L.; Skele-Stump, K.L.; Carbone, M.; Kane, A.B.; Testa, J.R. Activated TNF-alpha/NF-kappaB signaling via down-regulation of Pas-associated factor 1 in asbestos-induced mesotheliomas from Akr knockout mice. *Proc. Natl. Acad. Sci. USA* 2009, 106, 3420–3425. [CrossRef]

19. Hillegass, J.M.; Shukla, A.; Lathrop, S.A.; MacPherson, M.B.; Beuschel, S.L.; Butnor, K.J.; Testa, J.R.; Pass, H.I.; Carbone, M.; Steele, C.; et al. Inflammation precedes the development of human malignant meso-theliomas in a SCID mouse xenograft model. *Ann. N. Y. Acad. Sci.* 2010, 1203, 7–14. [CrossRef]

20. Guo, G.; Chmielecki, J.; Goparaju, C.; Heguy, A.; Dolgalev, I.; Carbone, M.; Seeo, S.; Meyerson, M.; Pass, H.I. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. *Cancer Res.* 2015, 75, 264–269. [CrossRef] [PubMed]

21. Bueno, R.; Stawiiski, E.W.; Goldstein, L.D.; Durinck, S.; De Rienzo, A.; Modrusan, Z.; Gnad, F.; Nguyen, T.T.; Jaiswal, B.S.; Chirieac, L.R.; et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. *Nat. Genet.* 2016, 48, 407–416. [CrossRef] [PubMed]

22. Nasu, M.; Emi, M.; Pastorino, S.; Tanji, M.; Powers, A.; Luk, H.; Baumann, F.; Zhang, Y.-A.; Gazdar, A.; Kanodia, S.; et al. High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma. *J. Thorac. Oncol.* 2015, 10, 565–576. [CrossRef] [PubMed]

23. Zhuo, Z.; Wan, Y.; Guan, D.; Ni, S.; Wang, L.; Zhang, Z.; Liu, J.; Liang, C.; Yu, Y.; Lu, A.; et al. A Loop-Based and AGO-Incorporated Virtual Screening Model Targeting AGO-Mediated miRNA–mRNA Interactions for Drug Discovery to Rescue Bone Phenotype in Genetically Modified Mice. *Adv. Sci.* 2020, 7, 1903451. [CrossRef]

24. Travis, W.D.; Brambilla, E.; Burke, A.P.; Marx, A.; Nicholson, A.G. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart; International Agency for Research on Cancer (IARC): Lyon, France, 2015.

25. Baas, P.; Fennell, D.; Kerr, K.M.; Van Schil, P.; Haas, R.L.; Peters, S. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* 2015, 26, v31–v39. [CrossRef] [PubMed]

26. Husain, A.N.; Colby, T.; Ordonez, N.; Krausz, T.; Attanoos, R.; Beasley, M.B.; Borczuk, A.C.; Butnor, K.; Cagle, P.; T.; C.; et al. Identification of Molecular Subtypes in Leiomyosarcoma. *Clin. Cancer Res.* 2015, 21, 779–789. [CrossRef] [PubMed]

27. Bertucci, F.; Finetti, P.; Rougemont, J.; Charafe-Jauffret, E.; Cervera, N.; Xerri, L.; Houlgatte, R.; Chirieac, L.R.; et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. *Nat. Genet.* 2016, 48, 407–416. [CrossRef] [PubMed]

28. Sorli, T.; Perou, C.M.; Tibshirani, R.; Aas, T.; Geisler, S.; Johnsen, H.; Hastie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc. Natl. Acad. Sci. USA* 2001, 98, 10869–10874. [CrossRef]

29. Le, Z.; Tan, I.; Das, K.; Deng, N.; Zouridis, H.; Pattison, S.; Chua, C.; Feng, Z.; Guan, Y.K.; Ooi, C.-H.; et al. Identification of Molecular Subtypes of Gastric Cancer With Different Responses to PI3-Kinase Inhibitors and 5-Fluorouracil. *Gastroenterology* 2013, 145, 554–565. [CrossRef] [PubMed]

30. Cristescu, R.; Lee, J.; Jebozhyin, M.; Kim, K.-M.; Ting, J.C.; Kong, S.S.; Liu, J.; Yue, Y.G.; Wang, J.; Yu, K.; et al. Molecular analysis of gastric cancer identifies subtype associated with distinct clinical outcomes. *Nat. Med.* 2015, 21, 449–456. [CrossRef] [PubMed]

31. Saddozi, U.A.K.; Wang, F.; Abkar, M.U.; Zhang, L.; An, Y.; Zhu, W.; Xie, L.; Li, Y.; Ji, X.; Guo, X. Identification of Clinical Relevant Molecular Subtypes of Pheochromocytoma. *Front. Endocrinol.* 2021, 12, 607. [CrossRef] [PubMed]

32. Wang, F.; Yan, Z.; Lv, J.; Xin, J.; Dang, Y.; Sun, X.; An, Y.; Qi, Y.; Jiang, Q.; Zhu, W.; et al. Gene Expression Profiling Reveals Distinct Molecular Subtypes of Esophageal Squamous Cell Carcinoma in Asian Populations. *Neoplasia* 2019, 21, 571–581. [CrossRef] [PubMed]

33. Guo, X.; Jo, V.Y.; Mills, A.M.; Zhu, S.X.; Lee, C.-H.; Espinosa, I.; Nucci, M.R.; Varma, S.; Forgó, E.; Hastie, T.; et al. Clinically Relevant Molecular Subtypes in Leiomyosarcoma. *Clin. Cancer Res.* 2015, 21, 3501–3511. [CrossRef] [PubMed]

34. Goldhirsch, A.; Wood, W.C.; Coates, A.S.; Gelber, R.D.; Thürlimann, B.; Senn, H.J. Strategies for subtypes–dealing with the diversity of breast cancer: Highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer. *Ann. Oncol.* 2011, 22, 1736–1747. [CrossRef]

35. Wilkerson, M.D.; Hayes, D.N. ConsensusClusterPlus: A class discovery tool with confidence assessments and item tracking. *Bioinformatics* 2010, 26, 1572–1573. [CrossRef] [PubMed]
84. Lai, C.; Sun, W.; Wang, X.; Xu, X.; Li, M.; Huang, D.; Xu, E.; Lai, M.; Zhang, H. RNAF43 frameshift mutations contribute to tumourigenesis in right-sided colon cancer. *Pathol. Res. Pr.* **2019**, *215*, 152453. [CrossRef] [PubMed]

85. Giannakis, M.; Hodis, E.; Mu, X.J.; Yamauchi, M.; Rosenbluh, J.; Cibulskis, K.; Saksena, G.; Lawrence, M.S.; Qian, Z.R.; Nishihara, R.; et al. RNAF43 is frequently mutated in colorectal and endometrial cancers. *Nat. Genet.* **2014**, *46*, 1264–1266. [CrossRef] [PubMed]

86. Jiang, X.; Hao, H.-X.; Crowney, J.D.; Wolffenden, S.; Bottiglio, C.; Ng, N.; Lu, B.; Hsieh, M.H.; Bagdasarian, L.; Meyer, R.; et al. Inactivating mutations of RNAF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 12649–12654. [CrossRef] [PubMed]

87. Ryland, G.L.; Hunter, S.M.; A Doyle, M.; Rowley, S.M.; Christie, M.; O’Brien, S.; Nicaise, C.; Bleikardt, E.; et al. Dasatinib in Imatinib-Resistant Philadelphia Chromosome-Positive Leukemias. *New Engl. J. Med.* **2006**, *354*, 2531–2541. [CrossRef]

88. Talpaz, M.; Shah, N.P.; Kantarjian, H.; Donato, N.; Nicoll, J.; Paquette, R.; Cortes, J.; O’Brien, S.; Ghosh, K.; Virshup, I.H.; et al. Wnt addiction of genetically defined cancers reversed by PORCN inhibition. *Oncogene* **2015**, *35*, 2197–2207. [CrossRef] [PubMed]

89. Li, C.; Cao, J.; Zhang, N.; Tu, M.; Xu, F.; Wei, S.; Chen, X.; Xu, Y. Identification of RSPO2 Fusion Mutations and Target Therapy. *Exp. Mol. Pathol.* **2022**, 102. Lopez-Rios, F.; Chuai, S.; Flores, R.; Shimizu, S.; Ohno, T.; Wakahara, K.; Illei, P.B.; Hussain, S.; Krug, L.; Zakowski, M.F.; et al.

90. Finn, R.S.; Crown, J.P.; Lang, I.; Boer, K.; Bondarenko, I.M.; Kulyk, S.O.; Ettl, J.; Patel, R.; Pinter, T.; Schmidt, M.; et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. *Lancet Oncol.* **2015**, *16*, 25–35. [CrossRef] [PubMed]

91. Dickson, M.A.; Schwartz, G.K.; Keohan, M.L.; D’Angelo, S.P.; Gounder, M.M.; Chi, P.; Antonescu, C.R.; Landa, J.; Qin, L.-X.; Crago, A.M.; et al. Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib. *JAMA Oncol.* **2016**, *2*, 937–940. [CrossRef] [PubMed]

92. Bahnassy, A.A.; Zekri, A.-R.; Abou-Bakr, A.A.; El-Deftar, M.M.; El Bastawisy, A.; Sakr, M.A.; El-Sherif, G.M.; Gaafar, R.M. Aberrant expression of cell cycle regulatory genes predicts overall and disease free survival in malignant pleural mesothelioma patients. *Exp. Mol. Pathol.* **2012**, *93*, 154–161. [CrossRef] [PubMed]

93. Bhamra, I.; Adams, N.; Armer, R.; Bingham, M.; McKeever, H.; Phillips, C.; Thompson, B.; Woodcock, S. Novel porcupine (PORCN) inhibitor RXC004: Evaluation in models of RNAF43 loss of function cancers. *J. Clin. Oncol.* **2017**, *35*, e14094. [CrossRef] [PubMed]

94. Dacic, S.; Kothmaier, H.; Land, S.; Shuai, Y.; Halbwedl, I.; Morbini, P.; Murer, B.; Comin, C.; Galateau-Salle, F.; Demirag, F.; et al. Global gene expression profiling of pleural mesotheliomas: Overexpression of Aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. *J. Cancer Res. Clin. Oncol.* **2016**, *142*, 148–156. [CrossRef] [PubMed]

95. Madan, B.; Ke, Z.; Harmston, N.; Ho, S.Y.; O’Frois, A.; Alam, J.; Jeyaraj, D.; Pendharkar, V.; Ghosh, K.; Virshup, I.H.; et al. Wnt addiction of genetically defined cancers reversed by PORCN inhibition. *Oncogene* **2015**, *35*, 2197–2207. [CrossRef] [PubMed]

96. Yan, J.; Yao, Y.; Yan, S.; Gao, R.; Lu, W.; He, W. Chiral Protein Supraparticles for Tumor Suppression and Synergistic Immunotherapy. *Nano Lett.* **2022**, 10, 1264–1266. [CrossRef] [PubMed]

97. Bhamra, I.; Adams, N.; Armer, R.; Bingham, M.; McKeever, H.; Phillips, C.; Thompson, B.; Woodcock, S. Novel porcupine (PORCN) inhibitor RXC004: Evaluation in models of RNAF43 loss of function cancers. *J. Clin. Oncol.* **2017**, *35*, e14094. [CrossRef] [PubMed]

98. Wu, Y.; You, M.; Meng, E.; Wang, S.; Niu, B.; Huang, W. Complete and durable response to crizotinib in a patient with malignant pleural mesothelioma harboring CD74-ROS1 fusion. *J. Cancer Res. Clin. Oncol.* **2022**, *148*, 2561–2566. [CrossRef] [PubMed]

99. Kobayashi, N.; Toyooka, S.; Yanai, H.; Soh, J.; Fujimoto, N.; Yamamoto, H.; Ichihara, S.; Kimura, K.; Ichimura, K.; Sano, Y.; et al. Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma. *Lung Cancer* **2008**, *62*, 120–125. [CrossRef] [PubMed]

100. Chung, C.T.; Santos, G.D.C.; Hwang, D.M.; Ludkovski, O.; Pintilie, M.; Squire, J.A.; Tsao, M.S. FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesotheliomas. *J. Pathol.* **2008**, *215*, 229–236. [CrossRef] [PubMed]

101. Dacic, S.; Kothmaier, H.; Land, S.; Shuai, Y.; Halbwedl, I.; Morbini, P.; Murer, B.; Comin, C.; Galateau-Salle, F.; Demirag, F.; et al. Global gene expression profiling of pleural mesotheliomas: Overexpression of Aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. *J. Cancer Res. Clin. Oncol.* **2016**, *142*, 12561–12566. [CrossRef] [PubMed]

102. Bahnassy, A.A.; Zekri, A.-R.; Abou-Bakr, A.A.; El-Deftar, M.M.; El Bastawisy, A.; Sakr, M.A.; El-Sherif, G.M.; Gaafar, R.M. Aberrant expression of cell cycle regulatory genes predicts overall and disease free survival in malignant pleural mesothelioma patients. *Exp. Mol. Pathol.* **2012**, *93*, 154–161. [CrossRef] [PubMed]

103. Bahnassy, A.A.; Zekri, A.-R.; Abou-Bakr, A.A.; El-Deftar, M.M.; El Bastawisy, A.; Sakr, M.A.; El-Sherif, G.M.; Gaafar, R.M. Aberrant expression of cell cycle regulatory genes predicts overall and disease free survival in malignant pleural mesothelioma patients. *Exp. Mol. Pathol.* **2012**, *93*, 154–161. [CrossRef] [PubMed]

104. Yan, J.; Yao, Y.; Yan, S.; Gao, R.; Lu, W.; He, W. Chiral Protein Supraparticles for Tumor Suppression and Synergistic Immunotherapy: An Enabling Strategy for Bioactive Supramolecular Chirality Construction. *Nano Lett.* **2020**, *20*, 5844–5852. [CrossRef] [PubMed]

105. Finn, R.S.; Crown, J.P.; Lang, I.; Boer, K.; Bondarenko, I.M.; Kulyk, S.O.; Ettl, J.; Patel, R.; Pinter, T.; Schmidt, M.; et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. *Lancet Oncol.* **2015**, *16*, 25–35. [CrossRef] [PubMed]

106. Dickson, M.A.; Schwartz, G.K.; Keohan, M.L.; D’Angelo, S.P.; Gounder, M.M.; Chi, P.; Antonescu, C.R.; Landa, J.; Qin, L.-X.; Crago, A.M.; et al. Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib. *JAMA Oncol.* **2016**, *2*, 937–940. [CrossRef] [PubMed]

107. Kuiper, J.L.; Ronden, M.I.; Becker, A.; Heideman, D.A.; Van Hengel, P.; Ylstra, B.; Thunnissen, E.; Smit, E.F. Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor. *J. Clin. Pathol.* **2015**, *68*, 320–321. [CrossRef] [PubMed]
108. Gopalan, P.K.; Pinder, M.C.; Chiappori, A.; Ivey, A.M.; Gordillo Villegas, A.; Kaye, F.J. A phase II clinical trial of the CDK 4/6 inhibitor palbociclib (PD 0332991) in previously treated, advanced non-small cell lung cancer (NSCLC) patients with inactivated CDKN2A. *J. Clin. Oncol.* **2014**, *32*, 8077. [CrossRef]

109. Levin, P.A.; Mayer, M.; Hoskin, S.; Sailors, J.; Oliver, D.H.; Gerber, D.E. Histologic transformation from adenocarcinoma to squamous cell carcinoma as a mechanism of resistance to EGFR inhibition. *J. Thorac. Oncol.* **2015**, *10*, e86–e88. [CrossRef]